Tetramethylpyrazine: A promising drug for the treatment of pulmonary hypertension
British Journal of Pharmacology2020Vol. 177(12), pp. 2743–2764
Citations Over TimeTop 10% of 2020 papers
Yuqin Chen, Wenju Lu, Kai Yang, Xin Duan, Mengxi Li, Xiuqing Chen, Jie Zhang, Meidan Kuang, Shiyun Liu, Xiongting Wu, Guofa Zou, Chunli Liu, Cheng Hong, Wenjun He, Jing Liao, Chi Hou, Zhe Zhang, Qiuyu Zheng, Jiyuan Chen, Nuofu Zhang, Haiyang Tang, Rebecca Vanderpool, Ankit A. Desai, Franz Rischard, Stephen M. Black, Joe G. N. Garcia, Ayako Makino, Jason X.‐J. Yuan, Nanshan Zhong, Jian Wang
Abstract
Our results suggest that TMP is a novel and inexpensive medication for treatment of PH. Clinical trial is registered with www.chictr.org.cn (ChiCTR-IPR-14005379).
Related Papers
- The inhibitory effect of tetramethylpyrazine ferulate on platelet aggregation(2003)
- Effects of tetramethylpyrazine on expression of Bcl-2 and Fas proteins in myocardial injury induced by catecholamine in rats(2004)
- Effect of Tetramethylpyrazine on 72 Cases of Cerebral Infarction(2007)
- Clinical study on treating vertigo of vertebrobasilar insufficiency with the combination of tetramethylpyrazine with xuehuzhuyu decoction.(2010)
- Study on tetramethylpyrazine protecting PC12 cell from apoptosis induced by diamide(2009)